# Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

> **NCT00327626** · PHASE2 · WITHDRAWN · sponsor: **Ionis Pharmaceuticals, Inc.**

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ISIS 113715

## Key facts

- **NCT ID:** NCT00327626
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-05-01
- **Primary completion:** 2007-02-01
- **Final completion:** 2007-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study was never started due to regional geopolitical conflict
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327626, "Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00327626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*